Clover Health should not be a public company, according to hedgeye's Health Policy Analyst Emily Evans. The insurance stock, which went public via SPAC and has been promoted by Chamath Palihapitiya, has been met with a heavy dose of criticism from Hindenburg Research and Hedgeye, which express their doubts about the true growth story and the transparency delivered by management. Hosted by Hope King.

Source: voices of wall street – Video: The Case for Why Clover Health Stock is Headed to Zero